To sign up     Investment     Messages    HR

 

Responsibility
Ever since the first transcatheter aortic valve replacement surgery conducted by professor Alain Cribier and his team in Rouen, France, 2002. Over 200,000 patients have benefited from the treatment. So far, there have been over 400 TAVR cases completed in China. Transcatheter aortic valve replacement (TAVR or TAVI) is a small invasive, low risk, arterial disease treatment; it brings the hope to the patients who suffer from severe aortic stenosis, especially those ones who are not suitable for open-heart surgeries. 
 
Venus Medtech has co-organized a “Heart Valve Research Institute” with The second of Affiliated hospital of ZheJiang University School of Medicine, which had an official kick start on March 24th, 2016. The institute has been qualified as the “Province Level Enterprise Institute” of ZheJiang province. The president of the Affiliated hospital of ZheJiang University School of Medicine, Wang Jian An is the director of the institute.